Metformin inhibits proliferation of residing fibroadipogenic progenitor cells from failing human hearts
Open Access
- 22 January 2026
- journal article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (1)
Abstract
Introduction: Evidence from randomized trials indicates beneficial effects of metformin treatment in heart failure with reduced ejection fraction (HFrEF), but mechanisms of action remain elusive. We investigated myocardial metformin distribution in vivo in HFrEF patients and explored its effects on cardiac fibrogenic progenitor cells from human HFrEF hearts in vitro. Methods: We assessed myocardial metformin distribution and its dependency on myocardial viability in seven HFrEF patients (ejection fraction: 36 ± 8%; median age: 67 years) using 11C-metformin positron emission tomography (PET), 15O-H2O-PET, and exercise stress echocardiography. We characterized myocardial cellular composition by fluorescence-activated cell sorting and single-cell RNA sequencing (scRNA-seq) on mononuclear cells isolated from explanted left ventricles from four HFrEF patients and four control human hearts. A population of fibroadipogenic progenitor cells (FAPs) was identified and incubated after differentiation with metformin to test the effects on proliferation. Results: Myocardial 11C-metformin kinetics were best described by reversible two-tissue-compartment kinetics. Global myocardial metformin net influx rate was 0.012 ± 0.007 ml ml−1 min−2, and the myocardium-to-blood ratio was 1.24 (95% confidence intervals: 1.03–1.44; P < .001) after 90 min. Regional myocardial metformin net influx correlated inversely with myocardial viability (r = −0.65, P = .04). By scRNA-seq, we identified cardiac FAPs expressing CD34 and PDGFRA, which transformed into extracellular matrix-forming myogenic cells upon activation. Incubation with metformin in clinically relevant doses (0.1 mM) inhibited FAP proliferation by 25%. Conclusion: Myocardial metformin uptake in HFrEF is marginal and confined to less viable and fibrotic regions. Cardiac FAPs are resident in human HFrEF myocardium and exhibit fibrogenic potential. Metformin inhibits FAP activation and proliferation at clinically relevant concentrations. These findings suggest that metformin may attenuate adverse left ventricular remodelling by targeting cardiac FAPs. Clinical trial registration: https://clinicaltrials.gov. Unique identifier: NCT03122769.Keywords
Funding Information
- Danish Diabetes and Endocrine Academy
- Novo Nordisk Fonden (OL8201)
- Novo Nordisk Fonden (NNF13OC0003882)
- Novo Nordisk Fonden (NNF21OC0072031)
- Novo Nordisk Fonden (NNF21OC0071718)
- Arvid Nilssons Fond (Dok1780631)
- Health Faculty at Aarhus University (phd0115)
- Hjerteforeningen (15-r99-a5947-22032)
- Hjerteforeningen (15-r99-a5947-22933)
- Kirsten Anthonius Memorial Fund
- Health Research Fund of Central Denmark Region
- Augustinus Fonden (15-4919)
- Aase og Ejnar Danielsens Fond (10-001657)
- Helga og Peter Kornings Fond (55027-100)
- Familien Hede Nielsens Fond
- A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
- P.A. Messerschmidt & Hustrus Foundation
- Danmarks Frie Forskningsfond (4183-00384)
- Danmarks Frie Forskningsfond (5053-00195)
- Danmarks Frie Forskningsfond (8048-00072A)
- Lundbeck Foundation (R396-2022-350)
- Diabetesforeningen
This publication has 49 references indexed in Scilit:
- The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT)American Heart Journal, 2021
- Metformin and heart failure–related outcomes in patients with or without diabetes: a systematic review of randomized controlled trialsHeart Failure Reviews, 2020
- A Randomised, Double-Blind, Placebo-Controlled Trial of Metformin on Myocardial Efficiency in Insulin-Resistant Chronic Heart Failure Patients without DiabetesEuropean Journal of Heart Failure, 2019
- Flow Cytometry and Cell Sorting Using Hematopoietic Progenitor Cells2019
- Metformin: clinical use in type 2 diabetesDiabetologia, 2017
- Therapeutic Concentrations of Metformin: A Systematic ReviewClinical Pharmacokinetics, 2015
- Cardiac fibroblasts: from development to heart failureJournal of Molecular Medicine, 2015
- Contrasting effects of chronic, systemic treatment with mTOR inhibitors rapamycin and metformin on adult neural progenitors in miceAGE, 2013
- Metformin Use and Mortality Among Patients With Diabetes and AtherothrombosisMetformin Use With Diabetes and AtherothrombosisArchives of internal medicine (1960), 2010
- Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical ImplicationsPharmaceutical Research, 2007